Wealthfront Advisers Adds $16M in CVS Health Corporation ($CVS)
The advisory firm increased its CVS Health position by 70.9%, adding 150,733 shares.
Key Points
- Wealthfront Advisers increased its stake in CVS Health by 70.9%, adding 150,733 shares to hold a total of 363,034 shares valued at $36.98 million.
- CVS Health's stock traded near $101.87 on Friday, with a market cap of $133.54 billion and a forward P/E ratio of 12.48.
- Several insiders sold shares in late May, and analysts from firms like Morgan Stanley and B of A Securities maintain a 'buy' rating with high targets.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Wealthfront Advisers increased its stake in CVS Health Corporation (NYSE:CVS), adding 150,733 shares to its portfolio. This move, reflecting a 70.9% increase, brings its total holdings to 363,034 shares, valued at approximately $36.98 million. The data comes from the latest Form 13F filing with the SEC, which covers holdings as of the most recent reporting period.
Wealthfront Advisers vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Wealthfront Advisers' CVS Health Position
Wealthfront Advisers boosted its position in CVS Health by 70.9%, increasing its shares from 212,301 to 363,034. This substantial addition of 150,733 shares highlights the firm's confidence in the healthcare company, with the investment now valued at $36.98 million.
Other Institutional Activity in CVS Health
Several other institutional investors also adjusted their positions in CVS Health. BlackRock, Inc. grew its holdings by 4.1%, adding 4,925,379 shares for a total of 125,919,853 shares valued at about $9.04 billion. Vanguard Capital Management LLC opened a new position with 82,650,076 shares worth approximately $5.94 billion. Meanwhile, Capital World Investors increased its stake by 14.2%, adding 9,585,731 shares to reach 77,248,642 shares, valued at $5.55 billion. On the other hand, State Street Corp slightly reduced its position by 1.4%, selling 861,562 shares, ending with 59,322,181 shares valued at $4.26 billion. Dodge & Cox and FMR LLC also decreased their holdings, with FMR LLC reducing by 23.9%.
CVS Health Corporation Stock Up 12.5%
Shares of CVS Health Corporation traded near $101.87 on Friday. The company has a market cap of $133.54 billion and a forward P/E ratio of 12.48. CVS Health's stock has experienced a 52-week low of $58.50 and a high of $104.94. The stock's 50-day moving average is $90.66, while the 200-day moving average is $80.81. With a beta of 0.623, CVS Health shows lower volatility compared to the market.
$CVS stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
In its most recent earnings report, CVS Health Corporation posted revenue of $405.62 billion, reflecting a growth rate of 6.1%. The company reported earnings per share (EPS) of $2.28, with a net margin of 0.723% and a return on equity of 3.75%. CVS Health is scheduled to announce its next earnings on July 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
11 analysts raised price targets.
-
EPS & revenue
EPS beat estimates by 15.8%. Revenue beat estimates by 4.6%.
-
Profit surprise
EBITDA beat by 15 percent. Operating income beat by 4 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
11 target raises.
-
Earnings quality
Operating margin up 1.1 points. Positive free cash flow.
Earnings Call Summary
CVS delivered a strong first quarter with $100.4 billion in revenue, up 6 percent year over year, and earnings per share of $2.57, beating consensus by 36 cents. The Aetna health insurance business showed major improvement with operating income up 1 billion dollars year over year and a better medical benefit ratio. Pharmacy sales grew 3 percent at existing stores driven by strong prescription volume increases. Management is focused on affordability, reducing friction in the health system, and launching a new consumer app called Health100 powered by artificial intelligence.
Guidance CVS raised full year earnings guidance to $7.30 to $7.50 per share, up from $7.00 to $7.20. They expect at least $405 billion in revenue for the year. Operating cash flow guidance improved to at least $9.5 billion.
Good report. The company beat and showed some forward improvement, with a few meaningful caveats.
Dividend
CVS Health offers an annual dividend rate of $2.66, yielding 2.54% based on its current stock price. The dividend payout ratio stands at 116.67%, indicating the company's commitment to returning value to shareholders.
Insider Buying and Selling at CVS Health Corporation
Recently, several insiders at CVS Health sold shares. On May 31, 2026, Amy Compton-Phillips, EVP and Chief Medical Officer, sold 7,618 shares at an average price of $90.98. On the same day, Brian Newman, EVP and Chief Financial Officer, sold 2,478 shares at the same price. Earlier, on May 20 and 21, Fernando Aguirre and Larry Robbins made multiple sales, with Robbins selling a total of 748,462 shares.
Analysts Set New Price Targets
Analysts continue to express optimism about CVS Health. On June 23, 2026, B of A Securities maintained a 'buy' rating with a price target of $110. Mizuho and Morgan Stanley also maintained 'buy' ratings with targets of $115 and $111, respectively. Overall, the consensus among 26 analysts is a 'strong buy', with a mean price target of $105.38.
About CVS Health Corporation
CVS Health Corporation, headquartered in Woonsocket, Rhode Island, provides a wide range of health solutions in the United States. Its operations span several segments, including healthcare benefits, pharmacy services, and retail operations. The company serves a diverse clientele, including individuals, employers, and government entities. CVS Health is a major player in the healthcare industry, employing approximately 219,000 people under the leadership of CEO J. David Joyner.
Bottom Line
Wealthfront Advisers' increased stake in CVS Health is a notable development, reflecting confidence in the company's prospects. CVS Health's stock performance and financial metrics, including its market cap and forward P/E ratio, make it a key player in the healthcare sector. While the information from the 13F filing is backward-looking, it provides valuable insight into institutional sentiment toward CVS Health.
Get CVS Health Corporation alerts
New 13F filings, insider trades, and analyst moves on $CVS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.